https://www.selleckchem.com/products/fm19g11.html
currence rate (≥1 symptom) was 22.2%. The risk of symptom recurrence was higher in patients with ≥2 versus 1 lesion (odds ratio [OR] 2.539; 95% CI 1.458-4.423; P = .001) and patients with moderate (OR 5.733; 95% CI 1.623-20.248; P = .007) or severe (OR 8.259; 95% CI 2.449-27.851; P = .001) pain versus none/mild pain. Triptorelin was well tolerated without serious adverse events.Triptorelin after conservative surgery for DIE improved symptoms over 24 months of follow up. The recurrence rate of symptoms was low and triptorelin was general